Fragments, network biology and designing multiple ligands

Drug Discovery Today

Volumn 12, Issue 3-4, 2007, Pages 156-160

  Morphy, Richard ^a   Rankovic, Zoran ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CANNABINOID; FLUOXETINE; GABAPENTIN; LIGAND; MEMANTINE; MORPHINE; NEUROKININ 1 RECEPTOR ANTAGONIST; OLANZAPINE; PROTEIN; RISPERIDONE;

ALZHEIMER DISEASE; DATA BASE; DRUG DESIGN; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESEARCH; DRUG SELECTIVITY; DRUG TARGETING; ENERGY; HUMAN; HYPERTENSION; LIPOPHILICITY; LOW DRUG DOSE; MOLECULAR SIZE; PAIN; PHYSICAL CHEMISTRY; REVIEW; X RAY CRYSTALLOGRAPHY;

CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; LIGANDS; MODELS, BIOLOGICAL; MOLECULAR WEIGHT; PHARMACOKINETICS; PROTEINS;

EID: 33846574259     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2006.12.006     Document Type: Review

References (28)

1. Roth B.L., et al. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov. 3 (2004) 353-359
2. Frantz S. Drug discovery: playing dirty. Nature 437 (2005) 942-943
3. Jeong H., et al. Lethality and centrality in protein networks. Nature 411 (2001) 41-42
4. Schmitt B.M. The concept of "buffering" in systems and control theory: from metaphor to math. ChemBioChem 5 (2004) 1384-1392
5. Huang S. Rational drug discovery: what can we learn from regulatory networks?. Drug Discov. Today 7 suppl. (2002) S163-S169
6. Morphy R., et al. From magic bullets to designed multiple ligands. Drug Discov. Today 9 (2004) 641-651
7. Morphy R., et al. Designed multiple ligands. an emerging drug discovery paradigm. J. Med. Chem. 48 (2005) 6523-6543
8. Lipinski C.A., et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23 (1997) 3-25
9. Vieth M., et al. Characteristic physical properties and structural fragments of marketed oral drugs. J. Med. Chem. 47 (2004) 224-232
10. Morphy R. The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds. J. Med. Chem. 49 (2006) 2969-2978
11. Morphy R., et al. The physicochemical challenges of designing multiple ligands. J. Med. Chem. 49 (2006) 4961-4970
12. Lowe J., et al. 1-Naphthylpiperazine derivatives as potential atypical antipsychotic agents. J. Med. Chem. 34 (1991) 1860-1866
13. Hann M.M., et al. Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci. 41 (2001) 856-864
14. Hopkins A.L., et al. Can we rationally design promiscuous drugs?. Curr. Opin. Struct. Biol. 16 (2006) 127-136
15. Erlanson D.A., et al. Fragment-based drug discovery. J. Med. Chem. 47 (2004) 3463-3482
16. Rees D.C., et al. Fragment-based lead discovery. Nat. Rev. Drug Discov. 3 (2004) 660-672
17. Lundstrom K. Structural genomics on membrane proteins: mini review. Comb. Chem. High Throughput Screen. 7 (2004) 431-439
18. Lipton S.A. Turning down, but not off. Nature 428 (2004) 473
19. Csermely P., et al. The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol. Sci. 26 (2005) 178-182
20. Collins M.O., et al. Molecular characterization and comparison of the components and multiprotein complexes in the postsynaptic proteome. J. Neurochem. 97 (2006) 16-23
21. 9-tetrahydrocannabinol and opioids after oral administration. J. Pharmacol. Exp. Ther. 304 (2003) 1010-1015
22. Field M.J. Gabapentin and the neurokinin1 receptor antagonist CI-1021 act synergistically in two rat models of neuropathic pain. J. Pharmacol. Exp. Ther. 303 (2002) 730-735
23. Keith C.T., et al. Multicomponent therapeutics for networked systems. Nat. Rev. Drug Discov. 4 (2005) 71-78
24. Andreadis E.A., et al. High-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension. J. Hum. Hypertens. 19 (2005) 491-496
25. Rasmussen K. Creating more effective antidepressants: clues from the clinic. Drug Discov. Today 11 (2006) 623-631
26. Schmitt G.J., et al. Striatal dopamine D2 receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: a comparative study with olanzapine. J. Psychopharmacol. 16 (2002) 200-206
27. Tauscher J., et al. Choosing the right dose of antipsychotics in schizophrenia: lessons from neuroimaging studies. CNS Drugs 15 (2001) 671-678
28. Parsons C.G., et al. Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist-a review of preclinical data. Neuropharmacology 38 (1999) 735-767